Screening for Individuals at Risk for Hereditary Breast and Ovarian Cancer: A Statewide Initiative, Georgia, 2012–2020

Abstract

Georgia implemented a statewide family history screening program for hereditary breast and ovarian cancer. From November 2012 through December 2020, 29 090 individuals were screened, 16 679 of whom (57.3%) self-identified as a racial/ethnic minority. Of the 4% (1172/29 090) of individuals who screened as high risk, more than half underwent genetic consultation (793/1172; 67.7%) and testing (416/589; 70.6%). Compared with White women, Black and Hispanic women had higher uptake rates of genetic consultation. Public health settings serving racial minorities are well suited to address disparities in genetic service access. (Am J Public Health. Published online ahead of print July 21, 2022:e1–e4. https://doi.org/10.2105/AJPH.2022.306932 )

Addressing disparities in cancer clinical trials: a roadmap to more equitable accrual

“…Furthermore, rural populations in Georgia bear the brunt of the state's cancer burden. 71.1% of Georgia's population, living in 149 of 159 counties, are medically underserved according to state defined criteria, and nearly 54% (85/159) of Georgia's counties are classified as rural based on the 2013 Rural-Urban Continuum Codes (16,17). Georgia's cancer mortality hotspots are concentrated in the eastern Piedmont to Coastal Plain, southwestern rural Georgia, and northern rural Georgia (16).…”

Just Dissemination of Genomics-Informed Public Health Applications: Time to Deepen Our Public Engagement Approaches

“…A universal feature of population screening is that most of those screened will be found to be at low genetic risk. In the case of HBOC, this is 85–95% of those who complete family history screening [ 15 ]. In our prior work, we found that African American women were more likely than white women to misunderstand negative HBOC screening results to mean they were at lower risk for breast cancer, rather than accurately understanding they were at lower risk for carrying a genetic mutation [ 16 ].…”